AgingResearch.NewsJoin free

AAV-NEUROD1 + AAV-DLX2

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 2 countries
  • Funders: National Institute on Aging and 2 more
  • Animals1

Outcomes

3

Astrocyte-to-neuron conversion rate

upin mice1+80%

1 study

  1. AAV-NEUROD1 + AAV-DLX2 increases astrocyte-to-neuron conversion rate in mice (80%).

    “astrocyte-to-neuron (AtN) conversion rate reached 80% in the striatum”

    Animalsin R6/2 and YAC128 HD mouse modelsstriatum

    Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease

    Nature communications27 Feb 2020

Motor function

upin mice1

1 study

  1. AAV-NEUROD1 + AAV-DLX2 improves motor function in mice.

    “NeuroD1 and Dlx2-treated R6/2 mice showed a significant extension of life span and improvement of motor functions.”

    Animalsin R6/2 mice

    Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease

    Nature communications27 Feb 2020

Lifespan

upin mice1

1 study

  1. AAV-NEUROD1 + AAV-DLX2 extends lifespan in mice.

    “NeuroD1 and Dlx2-treated R6/2 mice showed a significant extension of life span”

    Animalsin R6/2 mice

    Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease

    Nature communications27 Feb 2020

Latest

Related